Lundbeck Leaps Onto Longboard To Ride New Wave In Epilepsy

14 Oct 2024

Impressed by the data to date on bexicaserin for epileptic encephalopathies syndromes, the Danish drugmaker hopes the drug, through the acquisition of Longboard, will become a cornerstone of its new neuro-rare disease franchise.

Lundbeck HQ — Lundbeck's HQ in Valby, Copenhagen (Lundbeck)

Lundbeck has jumped onto the M&A merry-go-round and made a bid to buy Longboard Pharmaceuticals of the US and its closely watched anti-epilepsy drug bexicaserin.

The Denmark-based brain health specialist has agreed to acquire the La Jolla, CA-headquartered group in a $2.6bn deal, offering to...